美国透析患者贫血治疗的当代实践
该研究基于美国肾脏数据系统(USRDS)2016至2019年数据,描述维持性血液透析患者贫血治疗实践。近三分之二患者月血红蛋白为10.0-11.9 g/dl,ESA月均使用率76.7%,促红素α剂量略低于NHCT低目标组。ESA低反应性按高ERI定义患病率22.2%,按连续3-6个月血红蛋白<10 g/dl定义仅2.1%-6.0%。
要点
- 近2/3患者月血红蛋白在10.0-11.9 g/dl,ESA月使用率76.7%。
- 促红素α剂量略低于NHCT低目标组,ESA低反应性定义影响患病率。
- 持续低血红蛋白不常见,中位转铁蛋白饱和度22.3%提示铁缺乏可能。
核心结论
- 血红蛋白和ESA剂量分布稳定,促红素α剂量低于NHCT低目标组。
- 持续低血红蛋白不常见,可能反映铁缺乏。
研究设计与样本
- 分析美国肾脏数据系统(USRDS)2016至2019年成人机构内血液透析患者数据。
- 使用CROWNWeb数据集识别患者月血红蛋白、ESA利用(药物和累积剂量)、静脉铁利用、铁蛋白和转铁蛋白饱和度。
- 将研究期ESA剂量与1990年代NHCT试验剂量比较。
- 评估ESA低反应性:高红细胞生成素抵抗指数(ERI)和连续3或6个月血红蛋白<10 g/dl的患病率。
主要发现
- 近三分之二患者月血红蛋白为10.0至11.9 g/dl。
- ESA月均使用率为76.7%,聚乙二醇化促红素β使用增加。
- 促红素α剂量略低于NHCT低目标组。
- ESA低反应性按高ERI定义患病率为22.2%,按连续3至6个月血红蛋白<10 g/dl定义患病率为2.1%至6.0%。
- 高ERI且持续低血红蛋白患者的中位转铁蛋白饱和度为22.3%。
临床怎么用
- 当代透析患者血红蛋白多维持在10.0-11.9 g/dl,ESA使用普遍但剂量稳定。
- 评估ESA低反应性时需注意定义不同导致患病率差异巨大。
- 持续低血红蛋白患者应关注铁状态,转铁蛋白饱和度低提示铁缺乏可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The treatment of anemia is a major activity in the care of patients undergoing maintenance hemodialysis (HD). The comparative effectiveness of new pharmacologic treatments, relative to erythropoiesis-stimulating agents (ESAs), should be anticipated on the bases of controlled trials and current practice. We describe the contemporary practice of anemia treatment in a national cohort of patients undergoing maintenance HD. METHODS: We analyzed the United States Renal Data System (USRDS) data to identify adult patients undergoing in-facility HD in 2016 to 2019. Using the Consolidated Renal Operations in a Web-Enabled Network (CROWNWeb) dataset, we identified hemoglobin and ESA utilization (agent and cumulative dose) during each patient-month, as well as intravenous (IV) iron utilization, ferritin, and transferrin saturation. We compared ESA dosing during the study era to dosing in the Normal Hematocrit Cardiac Trial (NHCT), conducted in the 1990s. We assessed ESA hyporesponsiveness by estimating the prevalence of the following: (i) high erythropoietin resistance index (ERI) and (ii) either 3 or 6 consecutive months with hemoglobin <10 g/dl. RESULTS: Nearly two-thirds of patient-months had hemoglobin of 10.0 to 11.9 g/dl. Mean ESA utilization was 76.7% per month, with increasing use of pegylated epoetin beta. ESA dosing was stable; epoetin alfa dosing was slightly lower than in the low-target arm of the NHCT. The prevalence of ESA hyporesponsiveness was 22.2% if defined by high ERI, but only 2.1% to 6.0% if defined by 3 to 6 consecutive months with hemoglobin <10 g/dl. Median transferrin saturation was 22.3% with high ERI and persistently low hemoglobin. CONCLUSION: Hemoglobin and ESA dosing distributions are stable, with epoetin alfa dosing below the low-target arm of the NHCT. Persistently low hemoglobin occurs infrequently and may reflect iron depletion.
引用
- Weinhandl ED, Eggert W, Hwang Y, et al. Contemporary Practice of Anemia Treatment Among Dialysis Patients in the United States. Kidney Int Rep. 2023. PMID: 38106574. doi:10.1016/j.ekir.2023.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。